Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.

Abstract

An unexpected dramatic immune recovery was observed in a patient with full-blown AIDS receiving enfuvirtide-based antiretroviral therapy after multiple treatment failures. A complex interplay of viral and host factors, including the control of X4 viruses and proviral burden, may favor immune restoration with HIV neutralizing activity, despite persistent viremia.

• Authors: Alessandro Soria, Mariangela Cavarelli, Stefania Sala, Anna Ida Alessandrini, Gabriella Scarlatti, Adriano Lazzarin, Antonella Castagna
• Journal: Journal of medical virology (J Med Virol) Vol. 80 Issue 6 Pg. 937-41 (Jun 2008) ISSN: 0146-6615 [Print] United States
• PMID: 18428138 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• HIV Envelope Protein gp41
• HIV Fusion Inhibitors
• Peptide Fragments
• Enfuvirtide

Topics

• Acquired Immunodeficiency Syndrome (drug therapy, immunology, virology)
• Adult
• CD4 Lymphocyte Count
• CD4-Positive T-Lymphocytes (cytology, drug effects, immunology)
• Drug Resistance, Viral (genetics)
• Enfuvirtide
• Female
• HIV Envelope Protein gp41 (pharmacology, therapeutic use)
• HIV Fusion Inhibitors (pharmacology, therapeutic use)
• HIV-1 (drug effects, genetics)
• Humans
• Mutation
• Neutralization Tests
• Peptide Fragments (pharmacology, therapeutic use)
• Time Factors
• Viremia (drug therapy)